
Alector Inc (ALEC) Stock Forecast & Price Target
Alector Inc (ALEC) Analyst Ratings
Bulls say
Alector Inc's innovative therapeutic approach focuses on neurodegeneration through its advancement of therapies that enhance immune function in the brain, supported by a promising pipeline that includes AL001, AL002, AL003, and AL101. The company's differentiated transferrin receptor binding and tunable ABC platform have demonstrated significant brain uptake in non-human primates while maintaining favorable safety signals, which positions Alector competitively in the CNS drug delivery landscape. Additionally, with key programs targeting large indications and the potential for multiple paths to shareholder value, early clinical proof-of-concept data could act as substantial catalysts for the stock's positive outlook.
Bears say
Alector Inc faces significant challenges following the failure of the INFRONT-3 trial of latozinemab, which did not meet its primary endpoint and raises translational biology concerns. The company is at risk of failing its ongoing clinical trials for key products AL001 and AL002, potentially impacting its regulatory approvals and peak revenue forecasts. Additionally, inefficiencies in PGRN transport may undermine the therapeutic potential of Alector's products, further exacerbating uncertainties around future performance and investment viability.
This aggregate rating is based on analysts' research of Alector Inc and is not a guaranteed prediction by Public.com or investment advice.
Alector Inc (ALEC) Analyst Forecast & Price Prediction
Start investing in Alector Inc (ALEC)
Order type
Buy in
Order amount
Est. shares
0 shares